Argos Therapeutics Inc (ARGS) Insider Charles A. Nicolette Sells 92,001 Shares of Stock

Argos Therapeutics Inc (NASDAQ:ARGS) insider Charles A. Nicolette sold 92,001 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $0.16, for a total value of $14,720.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Argos Therapeutics Inc (ARGS) opened at $0.16 on Friday. Argos Therapeutics Inc has a 12 month low of $0.13 and a 12 month high of $5.68. The company has a market capitalization of $12.94, a price-to-earnings ratio of -0.14 and a beta of 1.38. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new stake in Argos Therapeutics Inc (NASDAQ:ARGS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.35% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

What are top analysts saying about Argos Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Argos Therapeutics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit